Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.94)
# 1,591
Out of 5,067 analysts
141
Total ratings
54.46%
Success rate
30.69%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $23.18 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $44.26 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $761.45 | +11.63% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.51 | +1,092.05% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.14 | +5,163.16% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $1.61 | +459.01% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $9.84 | +245.53% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $176.82 | +84.93% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $4.12 | +628.16% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $29.12 | +1,850.55% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $424.00 | -33.73% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.59 | +403.14% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.08 | +8,974.07% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $334.30 | -11.76% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $125.27 | -31.35% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $32.03 | +49.86% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.74 | +345.10% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $26.49 | +171.80% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $2.50 | +100.00% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $106.24 | -5.87% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $209.03 | -3.84% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $79.83 | +6.48% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $16.11 | +98.63% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $18.91 | +1,047.54% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $41.95 | +14.42% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $15.62 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $434.23 | -64.53% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $55.50 | +109.01% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $4.98 | +2,028.51% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $8.35 | +235.33% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $173.32 | -52.69% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $477.20 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.08 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.18
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $44.26
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $761.45
Upside: +11.63%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.51
Upside: +1,092.05%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.14
Upside: +5,163.16%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $1.61
Upside: +459.01%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $9.84
Upside: +245.53%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $176.82
Upside: +84.93%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $4.12
Upside: +628.16%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $29.12
Upside: +1,850.55%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $424.00
Upside: -33.73%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.59
Upside: +403.14%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.08
Upside: +8,974.07%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $334.30
Upside: -11.76%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $125.27
Upside: -31.35%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $32.03
Upside: +49.86%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $6.74
Upside: +345.10%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $26.49
Upside: +171.80%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $2.50
Upside: +100.00%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $106.24
Upside: -5.87%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $209.03
Upside: -3.84%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $79.83
Upside: +6.48%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $16.11
Upside: +98.63%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $18.91
Upside: +1,047.54%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $41.95
Upside: +14.42%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $15.62
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $434.23
Upside: -64.53%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $55.50
Upside: +109.01%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $4.98
Upside: +2,028.51%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $8.35
Upside: +235.33%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $173.32
Upside: -52.69%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $477.20
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.08
Upside: -